Results 61 to 70 of about 3,975 (165)

Identification of a Novel Small Molecule Facilitating HIV Elimination by the “Shock‐And‐Kill” Approach

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Antiretroviral therapy (ART) has markedly improved the prognosis of people living with HIV (PLWH); however, latent viral reservoirs remain a major barrier to a cure. The “Shock and Kill” strategy aims to reactivate latent provirus with latency‐reversing agents (LRAs) and subsequently eliminate the infected cells, yet most LRAs characterized to
Yuichiro Hara, Haruki Kitamura, Kouki Matsuda, Chieko Fujisaki, Sayaka Sukegawa, Kosuke Tanimoto, Kenji Maeda, Hiroaki Takeuchi   +7 more
wiley   +1 more source

Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up

Biomedicines
Background: Antiretroviral triple therapy has considerably reduced morbidity and mortality in people living with HIV and is the standard-of-care treatment. However, it is lifelong and linked to long-term side effects and adherence problems. Methods: Here,
Massimiliano Lanzafame, Emanuela Lattuada, Andrea Delama, Giovanni Mori, Sandro Vento   +4 more
doaj   +1 more source

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice

Drug Design, Development and Therapy, 2023
Diana Canetti,1 Laura Galli,1 Riccardo Lolatto,1 Silvia Nozza,2 Vincenzo Spagnuolo,1 Camilla Muccini,1 Benedetta Trentacapilli,2 Elena Bruzzesi,2 Martina Ranzenigo,2 Matteo Chiurlo,2 Antonella Castagna,1,2 Nicola Gianotti1 1Infectious Diseases Unit, San ...
Canetti D, Galli L, Lolatto R, Nozza S, Spagnuolo V, Muccini C, Trentacapilli B, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Gianotti N   +11 more
doaj  

Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Syrine Boujamline, Celine Boschi, Hugo Bes‐Barlandier, Christelle Tomei, Amelie Menard, Saadia Mokhtari, Isabelle Ravaux, Yacine Belkhir, Nadege Neant, Caroline Solas, Philippe Colson, Matthieu Million   +11 more
wiley   +1 more source

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

Retrovirology, 2022
Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve individuals living with HIV; these include first generation raltegravir ...
Alexa Vyain Zhao, Rustin D. Crutchley, Rakesh Chowdary Guduru, Kathy Ton, Tammie Lam, Amy Cheng Min   +5 more
doaj   +1 more source

Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States

HIV Medicine, Volume 27, Issue 9, Page 1517-1529, September 2026.
Abstract Objectives Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Adrian Khoei, Andrew Edmonds, Yen Chang, Catalina Ramirez, Mackenzie Vogan, Amanda Poliseno, Steven Wolinsky, Ken Ho, Todd T. Brown, Joseph B. Margolick, Jacquett Batson, Jennifer Hoffmann, Mark A. Marzinke, Mirjam‐Colette Kempf, Maria L. Alcaide, Joffi Effoe, Cecile D. Lahiri, Igho Ofotokun, Anandi N. Sheth, Stephen Gange, Audrey L. French, Bani Tamraz, Bradley E. Aouizerat, Phyllis C. Tien, Seble G. Kassaye, Jack DeHovitz, Kathryn Anastos, Kara W. Chew, Michelle Floris‐Moore, Julie B. Dumond   +29 more
wiley   +1 more source

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Human immunodeficiency virus (HIV) allosteric integrase inhibitors (ALLINIs) offer a vital alternative to standard therapies by targeting noncatalytic sites. By inducing aberrant integrase multimerization, they disrupt viral maturation. This review explores their medicinal chemistry evolution, detailing structural insights, structure–activity ...
Francesco Saccoliti, Elisa Patacchini, Emanuele Cara, Laura Zarbo, Antonella Messore, Aurora Albano, Giuseppe Ruggieri, Valentina Noemi Madia, Luigi Scipione, Roberta Costi, Roberto Di Santo   +10 more
wiley   +1 more source

Birth outcomes following bictegravir exposure during pregnancy.

OBJECTIVE: Bictegravir is increasingly prescribed as a co-formulated tablet with tenofovir alafenamide and emtricitabine to pregnant persons with HIV (PWH) despite limited pregnancy and birth outcome data.
Olivero, Rosemary, Sawyer, George, Yee, Lynn M, Hernandez-Diaz, Sonia, Chadwick, Ellen G, Patel, Kunjal, Williams, Paige L, Powis, Kathleen, Paul, Mary   +8 more
core   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source